Sucampo Pharmaceuticals Announces Fourth Quarter and Full Year 2012 Financial Results and Operating Highlights Teleconference

  Sucampo Pharmaceuticals Announces Fourth Quarter and Full Year 2012
  Financial Results and Operating Highlights Teleconference and Webcast

Business Wire

BETHESDA, Md. -- March 6, 2013

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), a global pharmaceutical company,
today announced that it will host a webcast and teleconference with senior
management to discuss its financial results and operating highlights for the
fourth quarter and full year ended December 31, 2012, on Wednesday, March 13,
2012, at 5:00 pm Eastern. The press release announcing the financial results
and operating highlights is expected to be released after the close of the
capital markets that day.

Investors interested in accessing the live audio webcast of the teleconference
may do so at
http://investor.sucampo.com/phoenix.zhtml?c=201197&p=irol-calendar and should
log on 10 to 15 minutes before the teleconference begins in order to download
any software required. Presentation slides will be available via the webcast
links. A replay of the webcast will also be available on the Company’s website
for several days after the live event. Alternatively, investors may dial
800-688-0836 (domestic) or 617-614-4072 (international) and use passcode
62809438. A replay of the teleconference will be available by dialing
888-286-8010 (domestic) or 617-801-6888 passcode 95378400, approximately two
hours after the teleconference concludes. The archive of the teleconference
will remain available for 30 days.

About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc. is a global pharmaceutical company focused on
innovative research, discovery, development and commercialization of
proprietary drugs based on prostones. The therapeutic potential of prostones
was first discovered by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo’s Chairman,
Chief Executive Officer, Chief Scientific Officer, and co-founder. Prostones,
naturally occurring fatty acid metabolites that have emerged as promising
compounds with unique physiological activities, can be targeted for the
treatment of unmet or underserved medical needs. For more information, please
visit www.sucampo.com.

Sucampo Forward-Looking Statement

This press release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements are based on management's current expectations and involve risks
and uncertainties, which may cause results to differ materially from those set
forth in the statements. The forward-looking statements may include statements
regarding product development, product potential, future financial and
operating results, and other statements that are not historical facts. The
following factors, among others, could cause actual results to differ from
those set forth in the forward-looking statements: the impact of
pharmaceutical industry regulation and health care legislation; Sucampo's
ability to accurately predict future market conditions; dependence on the
effectiveness of Sucampo's patents and other protections for innovative
products; the risk of new and changing regulation and health policies in the
US and internationally and the exposure to litigation and/or regulatory
actions.

No forward-looking statement can be guaranteed and actual results may differ
materially from those projected. Sucampo undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new information,
future events, or otherwise. Forward-looking statements in this presentation
should be evaluated together with the many uncertainties that affect Sucampo's
business, particularly those mentioned in the risk factors and cautionary
statements in Sucampo's most recent Form 8-K and 10-K, which the Company
incorporates by reference.

Contact:

Sucampo Pharmaceuticals, Inc.
Silvia Taylor, 1-240-223-3718
staylor@sucampo.com
 
Press spacebar to pause and continue. Press esc to stop.